13FGuru
Sign in with Google Sign in with Discord

NASDAQ · Health Care

MEDPACE HLDGS INC MEDP

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.

Sources StockAnalysis company profile stockanalysis.com
Biotechnology: Commercial Physical & Biological Resarch

Company profile

Business mix

  • The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas.
  • It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries.
  • In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials.
  • Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within diagnostics & research?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 4 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE 28.57 FCF 5.48% Buyback 8.94%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Baillie Gifford legacy James Anderson 0.2% $241.6M 2026-03-31
Giverny Capital Francois Rochon 4.5% $123.0M 2026-03-31
Vulcan Value Partners C.T. Fitzpatrick 2.6% $97.5M 2026-03-31
Fundsmith Terry Smith 0.2% $30.1M 2026-03-31

Recent trading changes over the last 3 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 0 Last 3 13F filing periods
Net reducers 4 Last 3 13F filing periods
Unchanged holders 0 Share count unchanged
Increase amount $0 Estimated from net added shares
Reduction amount $83.6M Estimated from net reduced shares
Net share change / base shares -14.5% -174,036 / 1,199,044
Fundsmith Terry Smith 3 filing periods
13F 2025-09-30 Filed 2025-11-14
Unchanged Shares 0.0% 13F value change $0
13F 2025-12-31 Filed 2026-02-17
Major reduction Shares -35.3% 13F value change -$19.2M
13F 2026-03-31 Filed 2026-05-15
Major reduction Shares -24.1% 13F value change -$16.3M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 127,537 Last 3 periods -64,869 (-50.9%) Total shares 62,668 Value $30.1M
Giverny Capital Francois Rochon 3 filing periods
13F 2025-09-30 Filed 2025-11-14
Minor increase Shares 0.0% 13F value change +$52.5M
13F 2025-12-31 Filed 2026-02-13
Minor increase Shares 0.6% 13F value change +$13.3M
13F 2026-03-31 Filed 2026-05-15
Minor reduction Shares -2.7% 13F value change -$24.9M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 261,755 Last 3 periods -5,674 (-2.2%) Total shares 256,081 Value $123.0M
Vulcan Value Partners C.T. Fitzpatrick 3 filing periods
13F 2025-09-30 Filed 2025-11-10
Major reduction Shares -30.4% 13F value change +$6.4M
13F 2025-12-31 Filed 2026-02-09
Major reduction Shares -76.4% 13F value change -$76.7M
13F 2026-03-31 Filed 2026-05-11
Major increase Shares 329.3% 13F value change +$70.9M
Settlement As of 13F 2026-03-31 · Filed 2026-05-11
Base shares 287,459 Last 3 periods -84,391 (-29.4%) Total shares 203,068 Value $97.5M
Baillie Gifford legacy James Anderson 3 filing periods
13F 2025-09-30 Filed 2025-10-31
Minor increase Shares 12.0% 13F value change +$136.8M
13F 2025-12-31 Filed 2026-01-23
Minor reduction Shares -6.4% 13F value change +$6.6M
13F 2026-03-31 Filed 2026-05-08
Minor reduction Shares -8.0% 13F value change -$65.6M
Settlement As of 13F 2026-03-31 · Filed 2026-05-08
Base shares 522,293 Last 3 periods -19,102 (-3.7%) Total shares 503,191 Value $241.6M

Recent mentions

No public mentions.